Diagnosis: COPD (Baseline FEV1 \<80% and FEV1/FVC \<70% of predicted normal values)
Severity of COPD: Stage I to IV
Group of COPD: Group B, or E, based on 2024 GOLD guideline (36)
Clinical stability: No acute exacerbation in the past 4 weeks. Patients with recent acute exacerbation in the past 4 weeks will be screened again in subsequent follow-up.
Moderate stress: PSS score ≥14 (28)
Access to a mobile device (e.g., a smartphone, tablet, or laptop) with internet connectivity
Ability to read, communicate, and provide written consent in Chinese.
You may not be if
Engaging in \>60 minutes/week of moderate PA based on American Lung Association guidelines
Recent or ongoing receipt of other pharmacological/behavioral trials within the past 3 months
Contraindications or severe comorbidities that may limit full participation (mental diseases, deafness, limb activity disorder, coronary heart disease, arterial aneurysm, uncontrolled hypertension, pregnancy, etc)
Co-existing respiratory diseases (Asthma/interstitial lung disease/bronchiectasis) or active malignancies
Very severe COPD requiring long-term oxygen therapy or home non-invasive ventilation
